Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusUpdate on the treatment of type 2 diabetes mellitusPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetesSodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and managementIn Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesA post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusDapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesFracture Risk in Type 2 Diabetes: Current Perspectives and Gender DifferencesPharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Dapagliflozin combination therapy in type 2 diabetes mellitus.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Diabetes Drug Effects on the Skeleton.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic miceReview article: effects of type 2 diabetes therapies on bone metabolism.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: post hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
P2860
Q26782225-0827308D-165E-4653-B4F3-07D04E8C043DQ28073342-A3496449-AE1C-4DBB-8B40-A134590179F4Q30249371-C11B8545-3BB1-4D94-84F4-25F48B78B2A6Q33890770-7681C49D-6E6F-42BF-8A39-AD5A0A6B51C4Q34460468-3A757815-F753-48A7-9771-08FDC317AFCFQ34726437-30563445-9A1A-4183-A1EE-36A0D236CEDCQ35137036-B5C7613E-B98F-4CE8-A235-C8690C8A21BDQ35595838-D2AF7344-A1C9-4814-9A8E-44FF19AD4B90Q35780861-0EB8F118-659A-4BD6-83E0-0C98F399419DQ36096350-3D7DD10A-DD78-4498-AC9D-A1690A963DADQ36180337-0A61D7CE-0C6A-4918-8771-36F544CD4546Q36345951-0BFE2611-B523-4631-9616-D357971A0A57Q36798684-15B36BFA-72FE-41C0-99EF-3C99F7E48285Q37060855-CDF71BD0-B32B-4141-A69F-96EED9C4C539Q37075620-B1BF639B-46AC-4F05-9CD0-BBA00F4DC42EQ37511845-1062F02C-A072-475B-91EA-B1F3DE761C6DQ38389823-994B81A4-1845-4EB2-8E9F-D863EA7F5F4CQ38619164-F1163634-3FDE-4649-BC5B-37FF5D1B2020Q38634051-D731A847-11E7-42DE-94FE-3C32E9E47915Q38645792-3109E74E-BC08-40A0-90E8-E0D9E9D03CD2Q38651175-506E3035-688C-4552-BEC3-6CDCB20E0D5FQ38715153-F840BB20-D913-432A-91D8-C7FF04416091Q38821464-1C5EA85D-F589-4EB4-91F5-DF8E873ADF81Q38906041-D7DBC8D7-D83D-4DAF-AF50-7466495F5162Q38931842-C6CAA88E-A8FF-4F7E-AFD0-F89E80F1792DQ38940175-C6BA8BA8-4B3F-4570-9D09-F58AF7FDF398Q38999214-9258A938-B410-49E1-ADC7-BD62909C1C49Q39006105-79BA0B6C-A2A9-4C7E-9271-8A05EDB9ABD9Q39170860-C5C9E3F2-A2ED-4E79-9EBA-1FF56732A4F1Q39290337-D7CDAE8A-FD10-491E-B7BF-3E35FD21B805Q39355218-6A672DDD-9670-4FA0-B250-A038991F9CA8Q39393777-F7371D5E-955C-4F61-A582-B09F909DB611Q39430445-C82EB609-F835-4176-A6B3-D50F11C13A49Q41551599-D9233408-A5A2-4C68-9B42-E5005D8CB1CAQ42329981-74F5D9B8-65F1-4016-83D7-31E11AB3A869Q42363966-8C27FCEF-9638-4024-A5BE-A91094BDF937Q47918474-D9463718-D376-4C21-91B0-91B918B3C2A0Q48664757-678ADE74-1274-4F1F-9C09-87F6B7A2FF5BQ49988051-D440A2C2-CF33-4929-A548-9919B437FE60Q58456988-02056230-6679-47A4-AD5A-2D38EF43F63B
P2860
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Safety profile of dapagliflozi ...... verall safety and rare events.
@en
Safety profile of dapagliflozi ...... verall safety and rare events.
@nl
type
label
Safety profile of dapagliflozi ...... verall safety and rare events.
@en
Safety profile of dapagliflozi ...... verall safety and rare events.
@nl
prefLabel
Safety profile of dapagliflozi ...... verall safety and rare events.
@en
Safety profile of dapagliflozi ...... verall safety and rare events.
@nl
P2093
P2860
P1433
P1476
Safety profile of dapagliflozi ...... verall safety and rare events.
@en
P2093
Agata Ptaszynska
Anne Marie Apanovitch
James F List
Kristina M Johnsson
Shamik J Parikh
Tjerk W A de Bruin
P2860
P2888
P304
P356
10.1007/S40264-014-0213-4
P577
2014-10-01T00:00:00Z